Exome Library Technology Provides Cost-Effective Sequencing

Targeted sequencing of exomes is an innovative technique to identify causative mutations for genetic disorders (both Mendelian and complex diseases) quickly and cost-effectively. By using new exome library technology with next-generation sequencing, the exome of a single genome can be sequenced for a fraction of the cost of whole-genome sequencing.

Roche NimbleGen (Madison, WI, USA) announces genomic services provider Ambry Genetics (Aliso Viejo, CA, USA) has officially become a certified service provider (CSP) for the NimbleGen SeqCap EZ Exome workflow. They will provide target-enrichment services using NimbleGen SeqCap EZ Human Exome combined with next-generation sequencing services for genetic research.

Ambry Genetics has passed a thorough certification test plan with precise experimental standards to join officially the Roche NimbleGen-Certified Service Provider Program. They will process customer gDNA samples for genomic enrichment, using 2.1 million optimized DNA probes from SeqCap EZ Exome to capture all human coding exons, and sequence the enriched samples using short-read, paired-end sequencing.

"Our genomics team has processed hundreds of samples for various projects utilizing many target-enrichment technologies. Ambry Genetics is very honored to have been selected by Roche NimbleGen as the first certified service provider in the United States offering the NimbleGen SeqCap EZ Human Exome product. With this addition, we are currently the only service provider in the world to offer the latest in sequence capture technologies to researchers,” said Ardy Arianpour, vice president of business development at Ambry Genetics.

"Roche NimbleGen is extremely excited to welcome Ambry Genetics as our first certified service provider in the United States. This addition will provide more researchers with access to the innovative NimbleGen SeqCap EZ Human Exome technology. Ambry Genetics' commitment to high quality genomic and next-generation sequencing services is an ideal fit with our SeqCap EZ Exome technology, and we look forward to this partnership and the innovation and value it will provide to the research market,” said Dr. Frank Pitzer, CEO of Roche NimbleGen, Inc.

Ambry Genetics is a College of American Pathology (CAP)-accredited, Clinical Laboratory Improvement Amendments (CLIA)-certified commercial clinical laboratory.

Related Links:
Roche NimbleGen
Ambry Genetics